08.11.2024  20:39:24 Zm. -0,19 Wolumen Bid20:40:19 Ask20:40:19 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
43,97USD -0,42% 405 810
Obrót: 12,02 mln
43,96Wolumen Bid: 300 43,97Wolumen Ask: 100 10,03 mldUSD - 29,30

Opis działalności

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
 

Zarząd & Rada nadzorcza

CEO
Thierry Bernard
Zarząd
Roland Sackers, Fernando Beils, Stephany Foster, Antonio Santos, Nitin Sood, Dr. Jonathan Sheldon, Jean-Pascal Viola
Rada nadzorcza
Lawrence A. Rosen, Dr. Metin Colpan, Dr. Toralf Haag, Elizabeth E. Tallett, Prof. Dr. Elaine Mardis, Prof. Dr. Ross L. Levine, Dr. Eva Pisa, Steve Rusckowski, Bert van Meurs, Eva van Pelt
 

Dane firmy

Nazwa: QIAGEN N.V.
Adres: Spoorstraat 50,NL-5911 KJ Venlo
Telefon: +31-77-320-8400
Fax: +31-77-320-8409
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
Przemysł: Biotechnologia
Sektor: Biotechnologia
Podsektor: Biotechnologia
Koniec roku finansowego: 31.12
Free float: 60,00%
Data IPO: 25.09.1997

Relacje inwestorskie

Nazwa: John Gilardi
Telefon: +49-2103-29-11711
Fax: -
E-mail: john.gilardi@qiagen.com

Główni akcjonariusze

Inne
 
70,50%
Sun Life Financial, Inc. (MFS)
 
10,50%
BlackRock, Inc.
 
9,30%
The Vanguard Group, Inc.
 
3,90%
Rue la Boetie SAS
 
2,90%
Norges Bank
 
2,90%